Nimbus Therapeutics has raised $105 million to put its allosteric TYK2 inhibitor through a clutch of phase 2 clinical trials. The multifront midphase program is designed to determine whether the drug ...

Officially known as NB.1.8.1 and nicknamed 'Nimbus', a new Covid-19 variant is now the dominant one in the United States. Detected in several US states back in June, the strain is now the most common ...

Fifty years ago, weather forecasting began a seismic shift, one which brought meteorology and weather forecasting to a level that would be impossible without this technology. The Nimbus program ...

Sotyktu (deucravacitinib), the tyrosine kinase 2 (TYK2) inhibitor for psoriasis from Bristol Myers Squibb Co., is “a good first-in-class” drug, said Nimbus Therapeutics LLC CEO Jeb Keiper, but his ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotech that integrates computational chemistry and other advanced technologies to design breakthrough medicines and transform drug ...

The impacts from the Nimbus satellites (Nimbus-1 pictured here) made a lasting mark on meteorology and climate science that can still be felt today. NASA Goddard Space Flight Center Growing up, my ...

Celgene and the computational chemistry company Nimbus Therapeutics are teaming up to advance R&D on small molecules that could treat a suite of immunology conditions. One Nimbus program is designing ...

FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) and Nimbus Therapeutics, LLC today announced that the companies have signed a definitive agreement under ...

Nimbus Therapeutics said yesterday it has won a $200 million milestone payment from Gilead Sciences based on progress in its clinical development of the allosteric acetyl-CoA carboxylase (ACC) ...

Looking for all the world like a buoy that sprouted wings, the National Aeronautics and Space Administration’s Nimbus weather satellite last week soared into space from its pad at Point Arguello, ...